Immediate Breast Reconstruction in a Patient Facing Postoperative Radiation
A 44-year-old woman with a 3.2 cm, grade 3, ER-positive, HER2-negative invasive ductal carcinoma of the left breast. She is a nonsmoker with a BMI of 27 and no comorbidities. She is scheduled for skin-sparing mastectomy and sentinel lymph node biopsy. The multidisciplinary tumor board recommends postmastectomy radiation therapy (PMRT) because of tumor size and grade. She wants immediate reconstruction and asks specifically about keeping her nipple and having a 'natural' result. She has not decided between implant-based and autologous reconstruction.
1. How does the recommendation for PMRT change your reconstructive plan, and what do you tell her about timing and options?
Read the worked answer
PMRT changes the calculus substantially. Radiation to a reconstructed breast increases the risk of capsular contracture, implant malposition, infection, and implant loss, and it can compromise the aesthetic result of an autologous flap as well (fat necrosis, volume loss, distortion). The key principle: if radiation is planned, avoid placing a permanent implant in the irradiated field, and if possible, perform autologous reconstruction or delay definitive reconstruction until after radiation.
Options to discuss:
- Immediate autologous reconstruction (e.g., DIEP or TRAM) at the time of mastectomy, accepting that the flap will be radiated. This is often preferred because the flap tolerates radiation better than an implant, and the patient gets a single-stage reconstruction.
- Staged approach: place a tissue expander at mastectomy, complete expansion before radiation, then exchange for a permanent implant after radiation. This is the most common implant-based pathway when PMRT is anticipated.
- Delay reconstruction until after PMRT is complete (typically 6-12 months), then perform autologous reconstruction. This gives the best chance of a durable, aesthetic result but means a period without reconstruction.
I would not place a definitive implant at the time of mastectomy in a patient who will receive PMRT. I would also discuss that nipple-sparing mastectomy is oncologically feasible in selected patients but that radiation increases the risk of nipple necrosis and malposition; her tumor size and grade make careful margin assessment essential, and nipple-sparing should be offered only if the nipple-areolar complex is clearly uninvolved and margins can be cleared.
The decision should be shared, with explicit discussion of the trade-offs: number of operations, recovery time, and the risk of revision. Document the discussion.
2. She chooses tissue expander placement with planned exchange after radiation. Two years later, she has a grade III capsular contracture and wants a 'natural' result. What are your options and how do you counsel her?
Read the worked answer
Grade III contracture (firm, visible distortion, symptomatic) after radiation in an implant-based reconstruction is a common and difficult problem. The irradiated capsule is fibrotic and poorly vascularized, so simple capsulectomy and implant exchange has a high failure rate.
Options:
- Total capsulectomy with implant exchange, ideally to a textured or polyurethane-coated device, with or without acellular dermal matrix. This can work but the recontracture rate in an irradiated field is significant.
- Conversion to autologous reconstruction: remove the implant and capsule, and perform a flap (DIEP, latissimus, or TRAM) either as a free flap or as a pedicled latissimus with or without an implant. In an irradiated field, autologous tissue is generally the most durable option for a soft, natural result.
- Fat grafting as an adjunct to improve contour and softness, but it does not correct a severe contracture alone.
Counseling: I would explain that the irradiated field is the main driver of her problem, that further implant-based surgery has a meaningful chance of recurrent contracture, and that autologous reconstruction offers the best chance of a durable, natural result but requires a longer operation and recovery and carries flap risks. I would review her goals, her tolerance for further surgery, and her body habitus (donor sites). I would also confirm oncologic follow-up is complete and that there is no evidence of recurrence before elective reconstruction. Shared decision-making, with realistic expectations about symmetry and the number of stages, is essential.